Gild stock forecast for FY2024 anticipates EPS beating

GILD stock forecast for FY2024 anticipates EPS beating consensus by 2–3%, bolstered by disciplined cost management. Balance sheet strength remains a differentiator in volatile biotech trade cycles. JPMorgan Lifts Gilead Sciences, Inc. ( GILD )’s Price Target To $145, Maintains Overweight Rating Year to date, the stock rose 28.2% compared with the industry ’s 3.7% gain. The stock has also outperformed the sector and the S&P 500 index in this time frame. Upward revisions to GILD stock forecast reflect improved analyst sentiment after positive trial data in HBV treatment. Sector-wide healthcare demand trends add to valuation support.